Qiagen 향후 성장
Future 기준 점검 1/6
Qiagen (는) 각각 연간 12.4% 및 6.1% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 11.9% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 13.4% 로 예상됩니다.
핵심 정보
12.4%
이익 성장률
11.91%
EPS 성장률
| Life Sciences 이익 성장 | 17.6% |
| 매출 성장률 | 6.1% |
| 향후 자기자본이익률 | 13.41% |
| 애널리스트 커버리지 | Good |
| 마지막 업데이트 | 18 May 2026 |
최근 향후 성장 업데이트
분석 기사 • Nov 08
Earnings Beat: Qiagen N.V. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
Shareholders might have noticed that Qiagen N.V. ( NYSE:QGEN ) filed its quarterly result this time last week. The...분석 기사 • Aug 08
Qiagen N.V. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
NYSE:QGEN 1 Year Share Price vs Fair Value Explore Qiagen's Fair Values from the Community and select yours The...Recent updates
새로운 내러티브 • May 15
Latent TB Testing Expansion And Automation Will Support Stronger Long Term Prospects
Catalysts About Qiagen Qiagen provides molecular diagnostics, sample preparation and bioinformatics tools used in clinical testing and research. What are the underlying business or industry changes driving this perspective?
새로운 내러티브 • Apr 30
Latent Tuberculosis And Research Pressures Will Constrain Progress Yet Long-Term Prospects Remain Intact
Catalysts About Qiagen Qiagen provides sample preparation, diagnostic testing and bioinformatics tools for molecular and clinical laboratories. What are the underlying business or industry changes driving this perspective?
내러티브 업데이트 • Apr 29
QGEN: Expect Balance Sheet Strength To Support Oncology And Diagnostic Platform Expansion
Qiagen's analyst price target has been adjusted modestly lower to $53.53 from $55.46 as analysts factor in a slightly higher discount rate, a marginally different profit margin outlook, and recent target cuts and rating changes across major banks, alongside some upward revisions earlier in the period. Analyst Commentary Recent research shows a mix of optimism and caution around Qiagen, with several firms adjusting price targets in both directions and a few making rating changes.내러티브 업데이트 • Apr 10
QGEN: I Expect Balance Sheet Strength To Drive Future Shareholder Returns
Qiagen's analyst price target is updated to $55.46. The modest change reflects mixed but generally constructive research commentary that cites an undemanding valuation, a robust balance sheet, and steady recent shareholder returns as key supports.내러티브 업데이트 • Mar 27
QGEN: Possible Sale Prospects Are Expected To Drive Future Returns
The analyst price target for Qiagen has been nudged higher to $55.46 from $55.23, as analysts cite an undemanding valuation, a robust balance sheet, and a track record of average annual shareholder returns of 13% as key supports for the updated view. Analyst Commentary Recent research on Qiagen presents a mix of optimism and caution, with several firms adjusting ratings and price targets while focusing on valuation, balance sheet strength, and execution risk.내러티브 업데이트 • Mar 12
QGEN: Possible Sale And Margin Upside Are Expected To Drive Future Returns
The Analyst Price Target on Qiagen has increased by $2, with analysts citing improved profit margin assumptions and a slightly lower future P/E multiple, while they refine discount rate and revenue growth inputs. Analyst Commentary Bullish and bearish analysts are split on Qiagen, with several firms lifting price targets while others trim estimates or ratings.내러티브 업데이트 • Feb 25
QGEN: Possible Sale And Fresh Takeover Interest Will Drive Future Upside
Analysts have raised their blended price target for Qiagen by about $0.63 to $55.23. This reflects updated views on slightly different revenue growth, profit margin and future P/E assumptions after a mix of recent target increases and reductions across the Street.내러티브 업데이트 • Feb 11
QGEN: Fairly Valued Outlook Will Hinge On Possible Sale And Execution Risks
Qiagen's analyst price target has edged up by about $1 to roughly $55, as analysts factor in slightly higher fair value and profit margin assumptions, along with a modest adjustment to growth expectations and P/E multiples. Analyst Commentary Recent Street research on Qiagen has been active, with several firms adjusting price targets in both directions and a few issuing downgrades.내러티브 업데이트 • Jan 28
QGEN: Fairly Valued Outlook Will Depend On Possible Sale And Leadership Transition
Analysts have slightly raised their Qiagen price target to about $53.32 from $53.23, reflecting small tweaks to revenue growth, discount rate, profit margin, and future P/E assumptions following recent downgrades in Street research. Analyst Commentary Bullish Takeaways Bullish analysts see the updated price target of about US$53.32 as still supported by long term earnings potential, even after recent revisions to revenue growth and profit margin assumptions.Seeking Alpha • Jan 27
Qiagen: Takeover Optionality With A High-Quality Consumables Platform
Summary QGEN is a consumable molecular diagnostics and life-science tools platform. They offer QuantiFERON, QIAstat-Dx, QIAcuity dPCR, and QDI bioinformatics. Recently, there’s renewed takeover speculation after reports that show they’re weighing strategic options. QGEN’s potential fits include Danaher or Agilent, with Thermo Fisher less likely after the 2020 deal talks failed. QGEN’s portfolio with Parse Biosciences adds single-cell sequencing scale, while 2026 automation launches would further deepen its differentiated workflow. I think QGEN now makes much more sense given the renewed M&A interest. But if deal talks fail or rumors cool, shares could de-rate, so my “Buy” rating is explicitly speculative. Read the full article on Seeking Alpha내러티브 업데이트 • Jan 08
QGEN: Fairly Valued Outlook Will Rely On Leadership Transition And Acquisitions
Narrative Update on Qiagen Analysts have lifted their Qiagen fair value estimate from approximately €50.43 to about €53.23, citing updated assumptions around revenue growth, profit margins and the P/E multiple applied to future earnings. What's in the News Qiagen plans a stock split or significant stock dividend with a 1 to 1.05263 ratio effective January 8, 2026, which adjusts the number of shares while keeping overall value aligned with the split terms (Key Developments).분석 기사 • Jan 07
An Intrinsic Calculation For Qiagen N.V. (NYSE:QGEN) Suggests It's 21% Undervalued
Key Insights The projected fair value for Qiagen is US$59.66 based on 2 Stage Free Cash Flow to Equity Qiagen is...내러티브 업데이트 • Dec 14
QGEN: Stable End Markets Will Support Gradual Sentiment Recovery Ahead
Analysts have trimmed their price target on Qiagen slightly, with a modest fair value reduction of about $0.36 per share. They cite still stable end markets, expectations for gradual improvement ahead, and a view that investment sentiment and valuations have largely bottomed.내러티브 업데이트 • Nov 29
QGEN: Gradual Improvement Ahead As End Markets Remain Stable And Sentiment Bottoms
Analysts have modestly lowered their price target for Qiagen from $55 to $53 per share, citing stable end markets and expectations of gradual improvement ahead. Analyst Commentary Analysts have provided a balanced view of Qiagen's current outlook, highlighting both opportunities and ongoing challenges as the company navigates a gradually improving market environment.내러티브 업데이트 • Nov 15
QGEN: Improving Sentiment And Stable Markets Will Set Stage For Future Upside
Analysts have slightly lowered their price target for Qiagen, reducing it by approximately $0.86 to reflect stable end markets. They also acknowledge that improvement is expected as investment sentiment stabilizes.분석 기사 • Nov 08
Earnings Beat: Qiagen N.V. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
Shareholders might have noticed that Qiagen N.V. ( NYSE:QGEN ) filed its quarterly result this time last week. The...내러티브 업데이트 • Oct 31
QGEN: Future Results Will Depend On Automation And Gradual Sentiment Recovery
Analysts have slightly lowered their price target for Qiagen from $55 to $53, citing stable end markets and anticipated gradual improvements in investment sentiment. Analyst Commentary Recent analyst updates highlight a nuanced outlook for Qiagen, with attention drawn to both its strengths and areas of potential risk in the near term.내러티브 업데이트 • Oct 17
Syndromic Diagnostics And Automation Will Shape Future Healthcare
Analysts have slightly lowered their price target for Qiagen, reflecting a small decrease from $51.79 to $51.64 per share. They cite ongoing stability in end markets and expectations for gradual valuation improvement.내러티브 업데이트 • Oct 03
Syndromic Diagnostics And Automation Will Shape Future Healthcare
Analysts have slightly reduced their fair value and price targets for Qiagen, with the consensus moving from approximately $52.39 to $51.79. This change is attributed to stabilizing end markets and expectations of gradual improvement in industry conditions.내러티브 업데이트 • Sep 04
Syndromic Diagnostics And Automation Will Shape Future Healthcare
Analysts remain cautiously optimistic on Qiagen, citing modest macroeconomic improvements and solid company execution despite persistent sector headwinds, resulting in an unchanged consensus price target of $52.39. Analyst Commentary Bullish analysts cite modest improvements in macroeconomic conditions, including easing tariff concerns, as supportive of Qiagen's shares.분석 기사 • Sep 02
Qiagen's (NYSE:QGEN) Strong Earnings Are Of Good Quality
Qiagen N.V.'s ( NYSE:QGEN ) earnings announcement last week was disappointing for investors, despite the decent profit...분석 기사 • Aug 08
Qiagen N.V. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
NYSE:QGEN 1 Year Share Price vs Fair Value Explore Qiagen's Fair Values from the Community and select yours The...분석 기사 • Aug 05
Qiagen N.V.'s (NYSE:QGEN) Share Price Could Signal Some Risk
NYSE:QGEN 1 Year Share Price vs Fair Value Explore Qiagen's Fair Values from the Community and select yours When close...Seeking Alpha • Feb 25
Qiagen N.V.: Some Clarity Needed Before Buying The Dip
Summary Qiagen N.V., a Netherlands-based medical diagnostics provider, faces market pressure due to some recent NIH funding concerns, despite strong financials and a diverse product portfolio. The company's free cash flow improved markedly in FY 2024, and the company announced a $300 million stock buyback program last month. An analysis around Qiagen N.V. follows in the paragraphs below. Read the full article on Seeking Alpha이익 및 매출 성장 예측
| 날짜 | 매출 | 이익 | 자유현금흐름 | 영업현금흐름 | 평균 애널리스트 수 |
|---|---|---|---|---|---|
| 12/31/2028 | 2,406 | 572 | 557 | 783 | 12 |
| 12/31/2027 | 2,272 | 467 | 529 | 743 | 16 |
| 12/31/2026 | 2,155 | 406 | 495 | 705 | 16 |
| 3/31/2026 | 2,099 | 402 | 404 | 615 | N/A |
| 12/31/2025 | 2,090 | 425 | 447 | 654 | N/A |
| 9/30/2025 | 2,071 | 405 | 473 | 658 | N/A |
| 6/30/2025 | 2,040 | 373 | 496 | 675 | N/A |
| 3/31/2025 | 2,003 | 94 | 503 | 680 | N/A |
| 12/31/2024 | 1,978 | 84 | 502 | 674 | N/A |
| 9/30/2024 | 1,966 | 93 | 460 | 633 | N/A |
| 6/30/2024 | 1,940 | 73 | 405 | 576 | N/A |
| 3/31/2024 | 1,939 | 337 | 358 | 521 | N/A |
| 12/31/2023 | 1,965 | 341 | 297 | 459 | N/A |
| 9/30/2023 | 1,954 | 332 | 275 | 432 | N/A |
| 6/30/2023 | 1,978 | 337 | 376 | 519 | N/A |
| 3/31/2023 | 1,999 | 353 | 430 | 580 | N/A |
| 12/31/2022 | 2,142 | 423 | 566 | 715 | N/A |
| 9/30/2022 | 2,226 | 488 | 660 | 826 | N/A |
| 6/30/2022 | 2,261 | 539 | 580 | 770 | N/A |
| 3/31/2022 | 2,313 | 563 | 556 | 755 | N/A |
| 12/31/2021 | 2,252 | 513 | 432 | 639 | N/A |
| 9/30/2021 | 2,240 | 311 | 516 | 745 | N/A |
| 6/30/2021 | 2,190 | 480 | 337 | 592 | N/A |
| 3/31/2021 | 2,065 | 449 | 239 | 571 | N/A |
| 12/31/2020 | 1,870 | 359 | 154 | 458 | N/A |
| 9/30/2020 | 1,713 | 191 | 10 | 298 | N/A |
| 6/30/2020 | 1,612 | 14 | 108 | 333 | N/A |
| 3/31/2020 | 1,550 | -31 | 152 | 302 | N/A |
| 12/31/2019 | 1,526 | -41 | N/A | 331 | N/A |
| 9/30/2019 | 1,516 | -25 | N/A | 332 | N/A |
| 6/30/2019 | 1,511 | 196 | N/A | 342 | N/A |
| 3/31/2019 | 1,507 | 188 | N/A | 356 | N/A |
| 12/31/2018 | 1,502 | 190 | N/A | 359 | N/A |
| 9/30/2018 | 1,496 | 90 | N/A | 325 | N/A |
| 6/30/2018 | 1,482 | 78 | N/A | 324 | N/A |
| 3/31/2018 | 1,453 | 55 | N/A | 275 | N/A |
| 12/31/2017 | 1,418 | 40 | N/A | 287 | N/A |
| 9/30/2017 | 1,387 | 89 | N/A | 311 | N/A |
| 6/30/2017 | 1,362 | 75 | N/A | 323 | N/A |
| 3/31/2017 | 1,347 | 82 | N/A | 353 | N/A |
| 12/31/2016 | 1,338 | 80 | N/A | 342 | N/A |
| 9/30/2016 | 1,320 | 123 | N/A | 328 | N/A |
| 6/30/2016 | 1,296 | 123 | N/A | 331 | N/A |
| 3/31/2016 | 1,281 | 126 | N/A | 303 | N/A |
| 12/31/2015 | 1,281 | 130 | N/A | 317 | N/A |
| 9/30/2015 | 1,293 | 104 | N/A | 310 | N/A |
| 6/30/2015 | 1,315 | 105 | N/A | 303 | N/A |
애널리스트 향후 성장 전망
수입 대 저축률: QGEN 의 연간 예상 수익 증가율(12.4%)이 saving rate(3.5%)보다 높습니다.
수익 vs 시장: QGEN 의 연간 수익(12.4%)이 US 시장(16.8%)보다 느리게 성장할 것으로 예상됩니다.
고성장 수익: QGEN 의 수입은 증가할 것으로 예상되지만 상당히 증가하지는 않을 것입니다.
수익 대 시장: QGEN 의 수익(연간 6.1%)이 US 시장(연간 11.7%)보다 느리게 성장할 것으로 예상됩니다.
고성장 매출: QGEN 의 수익(연간 6.1%)은 연간 20%보다 느리게 증가할 것으로 예상됩니다.
주당순이익 성장 예측
향후 자기자본이익률
미래 ROE: QGEN의 자본 수익률은 3년 후 13.4%로 낮을 것으로 예상됩니다.
성장 기업 찾아보기
기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2026/05/22 15:24 |
| 종가 | 2026/05/22 00:00 |
| 수익 | 2026/03/31 |
| 연간 수익 | 2025/12/31 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.
Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
Qiagen N.V.는 42명의 분석가가 다루고 있습니다. 이 중 16명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| Catherine Ramsey Schulte | Baird |
| Luke Sergott | Barclays |
| Charles Butler | Barclays |